中國旭陽(01907.HK)自研氨基醇產業化裝置投產 年產量5,000噸
中國旭陽集團(01907.HK)公布,其自主研發建設的氨基醇產業化裝置已建成投產,年產量達5,000噸,首批產品全線貫通,並通過品質驗收。
集團表示,該裝置為國內首套擁有完全自主知識產權的氨基醇產業化裝置,令集團成為全球第二個工業化生產氨基醇的企業。氨基醇是一種高性能助劑,廣泛應用於電子、新能源、化妝品、高端塗料、金屬精密切削、醫藥農藥中間體、碳捕集等領域。
旭陽集團計劃有序擴產,期望逐步形成氨基醇系列產品,構建以氨基醇為平台的多個產品線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.